Literature DB >> 23866158

Solifenacin-induced delirium and hallucinations.

Matej Štuhec1.   

Abstract

Solifenacin-induced cognitive adverse effects have not been reported frequently, but solifenacin-induced delirium and hallucinations with successful switching to darifenacin, without additional drug, have not been reported in the literature. In this case report, we present an 80-year-old Caucasian male with insomnia and anxiety symptoms and overactive bladder who developed delirium and hallucinations when treated with solifenacin and trazodone. After solifenacin discontinuation and switching to darifenacin, symptoms significantly improved immediately. Such a case has not yet been described in literature; however, an adverse effect associated with solifenacin can occur, as this report clearly demonstrates.
© 2013.

Entities:  

Keywords:  Antimuscarinic adverse effect; Case report; Darifenacin; Delirium; Hallucinations; Solifenacin

Mesh:

Substances:

Year:  2013        PMID: 23866158     DOI: 10.1016/j.genhosppsych.2013.06.002

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  4 in total

Review 1.  Anticholinergics for Overactive Bladder in Frail and Medically Complex Older People: The Case For.

Authors:  Adrian Wagg
Journal:  Drugs Aging       Date:  2018-09       Impact factor: 3.923

2.  Delirium following fesoterodine treatment for urgency incontinence in an 89-year old man.

Authors:  Jeannie Medeiros Charbonneau; Rania Bisset; Patrick Viet-Quoc Nguyen
Journal:  Can Urol Assoc J       Date:  2016-07-12       Impact factor: 1.862

Review 3.  Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations.

Authors:  Susie Orme; Vikky Morris; William Gibson; Adrian Wagg
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

Review 4.  Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature.

Authors:  Matej Štuhec
Journal:  Wien Klin Wochenschr       Date:  2015-01-10       Impact factor: 1.704

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.